SCYX Scynexis Inc

Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference at the Sofitel New York Hotel on Tuesday, September 27, 2016 at 3:00 p.m. ET.

A live webcast will be available on the investors section of the Company's website: www.SCYNEXIS.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

About SCYNEXISSCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of serious and life-threatening invasive fungal infections. For more information, visit www.SCYNEXIS.com.

CONTACT:

Media Relations
Blair Atkinson
MacDougall Biomedical Communications
Tel: 781.235.3060
batkinson@macbiocom.com

Investor Relations
Susan Kim
Argot Partners
Tel: 212.203.4433
susan@argotpartners.com